RxDoctor Payments Data

Kuldeep Shah, MD

Clinical Cardiac Electrophysiology · Dearborn, MINPI 1649685413

Payments from drug & device makers

What this record shows

This record is dominated by grants: $38,943 of the $54,098 with a category attached, or 72.0%. Medtronic accounts for 88.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2020 at $25,529 and has fallen 96.3% since, to $943 in 2025.

$54,098in general payments, 2019–2025

Across 141 payments — averaging $383.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$48K
  • Boston Scientific$3K
  • Abbott$1K
  • Medical Device Business Services, Inc.$563
  • Biotronik Inc.$439
  • Biosense Webster, Inc.$417
  • plus $433 from 7 others

What the payments were for

  • Grants$38,94372%
  • Travel & lodging$8,31815%
  • Food & beverage$6,40012%
  • Education$4371%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,098 in reported general payments places this provider in the 75th percentile of 105 clinical cardiac electrophysiology providers in Michigan.

See all clinical cardiac electrophysiology providers in Michigan

Medicare billing

Part B allowed, 2024
$132,688
Medicare patients
644
Services billed
2,166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban448$363,218
XareltoRivaroxaban70$49,974
EntrestoSacubitril/Valsartan39$37,214
FarxigaDapagliflozin Propanediol23$18,687
Flecainide Acetate119$3,168
Metoprolol Succinate287$3,134
Amiodarone Hcl107$2,003
Atorvastatin Calcium92$1,072
Diltiazem 24hr ErDiltiazem Hcl29$1,060
Warfarin Sodium155$1,014
Metoprolol Tartrate119$573
Pantoprazole Sodium38$468
ClopidogrelClopidogrel Bisulfate60$397
Carvedilol102$363
Losartan Potassium48$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$363,218448 claims
AstraZenecaFarxiga$104$18,68723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 105 clinical cardiac electrophysiology providers in Michigan.

Other clinical cardiac electrophysiology in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →